Collegium Pharmaceutical, Inc. reported significant financial growth for the fiscal year ending December 31, 2025, with total product revenues reaching $780.6 million, a 24% increase from $631.4 million in 2024. This growth was primarily driven by the full-year contribution of Jornay PM, which generated $111.7 million in revenue following its acquisition in September 2024. Other contributors included the Nucynta Products, which increased by $19.8 million, Belbuca with a $10.4 million rise, and Xtampza ER, which added $8.0 million. However, revenue from Symproic and other products saw a slight decline of $0.7 million.
The company's cost of product revenues also increased, totaling $317.3 million in 2025 compared to $254.1 million in the previous year. This rise was attributed to the full-year amortization of intangible assets acquired from the Ironshore acquisition, which accounted for $221.9 million in amortization expenses, up from $165.3 million in 2024. Selling, general, and administrative expenses rose to $284.8 million, reflecting increased salaries and marketing costs associated with the expanded sales force for Jornay PM.
Collegium's net income for 2025 was reported at $62.9 million, a decrease from $69.2 million in 2024. The decline was influenced by higher interest expenses, which rose to $82.3 million due to increased debt obligations following the Ironshore acquisition. The company also recorded a loss on extinguishment of debt amounting to $16.0 million, compared to $11.3 million in 2024. The effective tax rate for the year was 32.1%, slightly higher than the previous year's rate of 29.8%.
Strategically, Collegium has expanded its product portfolio and market presence through acquisitions, including the purchase of Ironshore, which has allowed the company to enter the ADHD market with Jornay PM. The company has also entered into an authorized generic agreement with Hikma Pharmaceuticals for the Nucynta Products, anticipating the launch of generic versions in early 2026. As of December 31, 2025, Collegium employed 423 full-time staff, reflecting its commitment to building a robust commercial organization.
Looking ahead, Collegium remains focused on leveraging its expanded product offerings and market presence to drive future growth. The company anticipates continued revenue generation from its existing products while navigating the challenges posed by competition and regulatory scrutiny in the opioid market. The management expressed confidence in its ability to maintain profitability and effectively manage its debt obligations, supported by strong cash flows from operations.
About COLLEGIUM PHARMACEUTICAL, INC
Collegium Pharmaceutical is a biopharmaceutical company focused on developing and commercializing differentiated products for serious medical conditions, including pain management and ADHD. Its portfolio features abuse-deterrent opioids, ADHD stimulants, and treatments for opioid-induced constipation. The company emphasizes innovative formulations, regulatory compliance, and intellectual property protection, serving healthcare providers and patients in the U.S. through a direct sales force and strategic licensing agreements.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.